CUSIP: 74371L109
Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,695,471
-
Share change
-
+217,429
-
Total reported value
-
$1,964,000
-
Price per share
-
$0.41
-
Number of holders
-
12
-
Value change
-
+$83,823
-
Number of buys
-
5
-
Number of sells
-
6
Quarterly Holders Quick Answers
What is CUSIP 74371L109?
CUSIP 74371L109 identifies PRTO - PROTEON THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2019
-
Previous quarter:
Q1 2019
Recent filing periods for CUSIP 74371L109:
Institutional Holders of PROTEON THERAPEUTICS INC - COM (PRTO) as of Q2 2019
As of 30 Jun 2019,
PROTEON THERAPEUTICS INC - COM (PRTO) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,695,471 shares.
The largest 10 holders included
Abingworth LLP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), RENAISSANCE TECHNOLOGIES LLC, Deer VII & Co. Ltd., GEODE CAPITAL MANAGEMENT, LLC, WEDBUSH SECURITIES INC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, NORTHERN TRUST CORP, and Raymond James Financial Services Advisors, Inc..
This page lists
12
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.